Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
reinforcing our confidence in mid-term growth outlook
Q1 sales
Cosentyx
USD 1.2 bn
+12%
1
GROWTH
CE Z KKǝL
Entresto
zolgensma
KISQALI
Kesimpta
LEQVIO®
USD 1.1 bn
USD 0.4 bn
USD 0.2 bn
USD 0.2 bn
nm
+42%
+18%
+28%
nm
nm
Est. CAGR (2020-26)
Low double digit
Peak sales USD >7bn
US LOE 2029+
Est. CAGR (2020-26)
Double digit until LoE
Peak sales USD >5bn
US LOE 2025-2036
Est. CAGR (2020-26)
Low to mid teens
Peak sales multi-bn¹
US LOE 2031+
Est. CAGR (2020-26)
Low 30s²
Peak sales multi-bn
US LOE 2031+
Est. CAGR (2020-26)
nm
Peak sales multi-bn
US LOE 2031+
Est. CAGR (2020-26)
nm
Peak sales multi-bn
US LOE 2036+
nm not meaningful. All growth rates in constant currencies (cc). US LoEs are estimated based on relevant patents; further extensions possible. 1. Including ZolgensmaⓇ IT. 2. Including KisqaliⓇ adjuvant.
7 Investor Relations | Q1 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation